Importance of PET for surgery of gastrointestinal stromal tumors;Bedeutung der PET für die Chirurgie des gastrointestinalen Stromatumors

Chirurg

Volumn 85, Issue 6, 2014, Pages 493-499

  Ronellenfitsch, U ^a   Wangler B ^a   Niedermoser, S ^a   Dimitrakopoulou Strauss, A ^b   Hohenberger, P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Gastrointestinal stromal tumors; Multimodal treatment; Positron emission tomography; Theranostics; Tracer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; DIAGNOSTIC USE; ENERGY METABOLISM; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMAN; MOLECULAR IMAGING; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

COMBINED MODALITY THERAPY; ENERGY METABOLISM; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR IMAGING; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 84902374169     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-013-2670-1     Document Type: Article

References (39)

1. NCCN clinical practice guidelines in oncology - soft tissue sarcoma. http://www. nccn. org/professionals/physician_gls/pdf/sarcoma. pdf.
2. Abuzakhm SM, Acre-Lara CE, Zhao W et al (2011) Unusual metastases of gastrointestinal stromal tumor and genotypic correlates: case report and review of the literature. J Gastrointest Oncol 2: 45-49.
3. Ahmadzadehfar H, Biersack HJ, Ezziddin S (2010) Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 40: 105-121.
4. Apostolopoulos DJ, Dimitrakopoulou-Strauss A, Hohenberger P et al (2011) Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 38: 1212-1223.
5. Asakawa C, Ogawa M, Kumata K et al (2011) [11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. Bioorg Med Chem Lett 21: 2220-2223.
6. Benezra M, Hambardzumyan D, Penate-Medina O et al (2012) Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia 14: 1132-1143.
7. Blanke CD, Demetri GD, Mehren M von et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620-625.
8. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759.
9. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58.
10. DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245: 347-352.
11. Demetri GD, Mehren M von, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
12. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U et al (2007) 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med 48: 1245-1250.
13. Dimitrakopoulou-Strauss A, Pan L, Strauss LG (2012) Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging 12: 283-289.
14. Duensing S, Duensing A (2010) Targeted therapies of gastrointestinal stromal tumors (GIST) - the next frontiers. Biochem Pharmacol 80: 575-583.
15. Eisenberg BL, Harris J, Blanke CD et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99: 42-47.
16. Fiore M, Palassini E, Fumagalli E et al (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35: 739-745.
17. Glekas AP, Pillarsetty NK, Punzalan B et al (2011) In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J Nucl Med 52: 1301-1307.
18. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
19. Hohenberger P, Ronellenfitsch U, Oladeji O et al (2010) Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 97: 1854-1859.
20. Joensuu H, Fletcher C, Dimitrijevic S et al (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3: 655-664.
21. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056.
22. Jones RL, McCall J, Adam A et al (2010) Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 36: 477-482.
23. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259-1269.
24. Koukouraki S, Strauss LG, Georgoulias V et al (2006) Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33: 1115-1122.
25. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83.
26. Mussi C, Ronellenfitsch U, Jakob J et al (2010) Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 21: 403-408.
27. Park JW, Cho CH, Jeong DS et al (2011) Role of F-fluoro-2-deoxyglucose positron emission tomography in gastric GIST: predicting malignant potential pre-operatively. J Gastric Cancer 11: 173-179.
28. Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: 2325-2331.
29. Slobbe P, Poot AJ, Windhorst AD et al (2012) PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today 17: 1175-1187.
30. Sogawa C, Tsuji AB, Sudo H et al (2010) C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nucl Med Biol 37: 179-187.
31. Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment - pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251: 447-456.
32. The ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7): 49-55.
33. Treglia G, Mirk P, Stefanelli A et al (2012) 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. Clin Imaging 36: 167-175.
34. Wang JQ, Miller KD, Sledge GW et al (2005) Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett 15): 4380-4384.
35. Wardelmann E, Buttner R, Merkelbach-Bruse S et al (2007) Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451: 743-749.
36. Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749.
37. West RB, Corless CL, Chen X et al (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165: 107-113.
38. Yoshikawa K, Shimada M, Kurita N et al (2013) The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. Surg Today 43: 1162-1167.
39. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782.